t
On 9 November 2026, Renalytix plc confirmed that SP Angel Corporate Finance LLP and Oberon Capital have initiated equity research coverage on the company. The newly published research notes are available on Research Tree as well as on the respective research portals of SP Angel and Oberon Capital.
| Date | 9 Nov 2026 |
| Time | 15:01:06 |
| Category | Corporate updates |
| ID | 4111C |
Renalytix plc
(“Renalytix” or the “Company”)
Publication of Equity Research
LONDON and NEW YORK, 9 November 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that SP Angel Corporate Finance LLP and Oberon Capital have initiated coverage on the Company.
The new equity research notes are both available on Research Tree (https://www.research-tree.com/) and have been published on the following research portals:
SP Angel Corporate Finance
https://www.spangel.co.uk/research/
Oberon Capital
https://oberoninvestments.com/research-and-events-portal/
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke (Corporate Finance) |
|
|
|
Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Heena Karani |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.
RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.